Kodiak Sciences' Two Wet AMD Therapies Meet Primary Endpoints in Phase III Trial

Kodiak Sciences announced that its experimental therapies, Zenkuda and tabirafusp-ted, demonstrated non-inferiority to aflibercept in the Phase III DAYBREAK study for wet age-related macular degeneration. At week 48, Zenkuda patients gained an average of 7.2 letters and tabirafusp-ted patients gained 6.3 letters, compared to 7.6 letters for aflibercept. Additionally, 54% of Zenkuda patients achieved 24-week extended dosing intervals. Following the initial announcement on September 28, 2026, which sent Kodiak shares up over 162%, the company plans to submit a multi-indication Biologics License Application for Zenkuda in the fourth quarter of 2026.